Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

Tagrisso tops rival drugs on survival in first-line lung cancer

Tagrisso tops rival drugs on survival in first-line lung cancer

The improvement in OS came over other drugs in the EGFR inhibitor class, namely AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib), and according to AZ’s head of ... Now, the new data should help AZ continue to build momentum with Tagrisso

Latest news

  • Hansoh Pharma shares head skyward after HKEX debut Hansoh Pharma shares head skyward after HKEX debut

    Six other new chemical entities are in the mid- to late-stage pipeline, including a third-generation EGFR inhibitor that could be a rival to AstraZeneca’s Tagrisso (osimertinib) in China ... and has been filed for EGFR-positive non-small cell lung

  • Oncology drives AstraZeneca, Genzyme boosts Sanofi Oncology drives AstraZeneca, Genzyme boosts Sanofi

    Third generation EGFR inhibitor Tagrisso is now the company’s top-selling drug, bringing in sales of $630m in the first quarter, almost double what the lung cancer drug made during ... Its Merck &Co-partnered PARP inhibitor Lynparza, which has

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    combination with the latter’s EGFR inhibitor Tagrisso (osimertinib) and PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in a series of proof-of-concept trials in solid tumours. ... Following after is surufatinib, an inhibitor of VEGF, FGFR and CSF-1R

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    Undeterred, Pfizer ran a third trial called ARCHER 1050 that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib), although ... it got a green light for PARP inhibitor

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    expression and overall survival rates, casting a cloud over PD-L1 checkpoint inhibitor Imfinzi in this setting. ... patients who have progressed on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment.

More from news
Approximately 1 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics